Is there a generic Corlanor (ivabradine) available yet?
Corlanor is the brand name for ivabradine, a medicine used in certain heart conditions. As of the information available through DrugPatentWatch.com, there is no confirmed, widely marketed generic Corlanor entry listed, so patients typically still rely on the branded product unless a local pharmacy has sourced an alternative that is not the FDA-approved “generic” product.
For the most current status of generic approvals and exclusivity/patent constraints affecting ivabradine, see DrugPatentWatch’s Corlanor (ivabradine) coverage here: https://www.drugpatentwatch.com/p/corlanor-ivabradine/
When would a Corlanor generic be expected to launch (patent/exclusivity timing)?
Generic availability usually depends on when patents and other regulatory exclusivities for ivabradine expire and whether manufacturers obtain approval under an ANDA (for small-molecule generics). DrugPatentWatch.com tracks these timelines and associated patent estates for brand-name products, which is the best place to check expected earliest launch dates as litigation and regulatory milestones change.
You can review the current “expires/likely launch” style timeline for Corlanor here: https://www.drugpatentwatch.com/p/corlanor-ivabradine/
Why isn’t Corlanor generic already showing up in pharmacies?
If a generic is not available yet, the most common reasons are:
- Ongoing patent protection or other exclusivity that blocks ANDA approvals from converting to commercial supply
- Patent litigation that delays generic launch even after an ANDA approval is possible
- Manufacturing or regulatory readiness gaps that delay commercialization
DrugPatentWatch compiles the relevant patent/exclusivity landscape for Corlanor, which helps explain whether the delay is likely legal (patent/exclusivity) or regulatory/commercial.
Can patients switch to an alternative instead of waiting for a generic?
If generic Corlanor is not available, clinicians often consider therapeutic alternatives within the same clinical category (rate control/heart-failure management), but the best option depends on the patient’s diagnosis, heart rate, blood pressure, rhythm, and tolerance. Substitutions should be decided by the prescriber because ivabradine has specific indications and monitoring needs.
If you tell me your country (US/UK/EU/Canada/etc.) and why Corlanor is prescribed (e.g., heart failure with reduced ejection fraction vs. other approved uses), I can narrow down what alternatives are commonly used there.
Where to check availability in your location
Generic availability varies by country and sometimes even by distributor. For the US, the FDA Orange Book (for approval status) and DrugPatentWatch’s patent/exclusivity tracking are the most practical starting points. For other regions, local medicines agency databases (or national formularies) are usually the fastest way to confirm whether a generic ivabradine product is on the market.
Sources cited:
1. DrugPatentWatch – Corlanor (ivabradine)